The First Broad Reset Since 2018 Cuts Chemistry Sixteen Per Cent

CMS published the preliminary CY 2027 Clinical Laboratory Fee Schedule rates on 21 September 2026 — the second full data cycle under the Protecting Access to Medicare Act, and the first broad rate reset since 2018. Chemistry came in at −16% across 387 codes. That it was the smallest cut of the routine categories is the part worth reading twice.

What the document actually says

Of 1,947 applicable HCPCS codes, 1,528 — 78.5% — received a weighted median calculated from private payor data. Of those, 1,171 came in below the CY 2026 fee schedule rate, 186 above, and 169 unchanged. CMS puts the average potential change across the schedule at roughly 16% lower. The categories are not cut equally, and the ordering is the finding.

Chemistry is the highest-volume block in the schedule and the base of the USD 16.8 billion market tracked in our clinical chemistry and urinalysis report. It took the smallest cut of the five routine categories. Genomic sequencing took the largest. Proprietary laboratory analysis — the category for tests with no comparable analogue — was barely touched.

A PAMA weighted median measures exactly one thing: how far the private price had drifted above the Medicare price, weighted by the volume each payor actually pays at. Where the gap was wide, the cut is large. Where private payors had already pushed the price close to the government’s, the cut is small. Chemistry’s −16% is therefore not a statement that private payors were generous with routine chemistry. It is a statement that routine chemistry had already been bought down close to a commodity price before the reset arrived. The reset did not make chemistry a commodity. It confirmed that it already was one.

The cap is the mechanism, not the relief

The Consolidated Appropriations Act, 2026 amended the statute to phase reductions across 2027 to 2029, capping any single test’s annual reduction at 15% against the amount established for it in the preceding year. The American Clinical Laboratory Association reads the preliminary file as almost 1,200 tests reduced, including 775 tests at the full 15% in the first year, and CMS projects the change at roughly USD 1 billion a year of Medicare savings.

A cap that binds on 775 tests is not softening anything. It is evidence that the underlying medians sit far enough below current rates that a 15% annual limit takes three years to arrive at them. The phase-in converts a one-year price event into a three-year compression, which is materially worse for anyone planning a reagent contract than a single clean cut would be.

Where the data came from is contested, and both sides are right

CMS reports 6,411 laboratories submitting data, 6,304 used after exclusions. It also notes that hospital laboratories were 1.1% of reporting applicable laboratories in 2017 and about 13.6% in this cycle, following the 2019 rule changes that let hospital outreach laboratories report at TIN level rather than NPI level.

ACLA’s objection is coverage: the rates rest on data from about 2% of all laboratories paid under Part B in 2024, fewer than 20% of hospital outreach laboratories, and more than 4,000 independent laboratories that reported nothing at all.

Both statements are accurate and they do not cancel out. The composition of who reports has improved structurally. The coverage of who is paid has not. A weighted median computed over a self-selected minority is still a weighted median — it is a median of a different population from the one the schedule prices. That matters for this market in a specific, directional way: if the reporting base skews toward larger and lower-cost laboratories, the resulting median is biased downward, and part of the 2027 cut is measurement rather than market. We cannot separate the two from the published file. Anyone who claims to has assumed the answer.

The other price-setting document moved in the same year

China’s inter-provincial alliance led by Jiangxi awarded 2,314 specifications of biochemical testing reagents from 154 enterprises across 35 items, at an average reduction of 70% against ceiling price and, for some items, more than 98%. Selected prices included 0.07 yuan per test for calcium and for glucose, and 0.06 yuan for phosphorus; at least one bid came in at 0.03 yuan. The procurement cycle runs two years, with price linkage across 26 provinces, and implementation from 28 April 2026.

Put the two documents side by side. The United States moves the administered price of a chemistry test by 16% through a statutory weighted median, phased over three years and argued over in public comment. China moves it by 70% in a single award with a floor near zero. Neither is a competitive event in the ordinary sense. In both systems the price of routine chemistry is now an administrative variable, and the vendor’s task in both is to survive a number it did not set.

What it does to a forecast that assumes a price

Our base for this discipline is USD 16.8 billion in 2025 rising to USD 22.49 billion in 2033 — a 3.71% CAGR — on reportable results growing 5.13% a year while realised revenue per result falls from USD 0.78 to USD 0.70.

A 16% cut to a fee schedule does not subtract 16% from that. The schedule sets the laboratory’s revenue per test. The reagent price the vendor receives is a negotiated share of the laboratory’s cost of producing a reportable result. Transmission runs at contract renewal rather than at publication, and it is partial: some of the cut lands on the laboratory’s margin, some on the reagent price, and some is recovered by pushing more volume through an analyser base that is already paid for. That is why a statutory cut of this size and a forecast of 3.71% are consistent with each other, and why reading the fee schedule as a direct revenue forecast for vendors is the most common error made with it.

Our downside case is correspondingly modest. If the US cap binds fully through 2029 and China adds five provinces to the alliance, 2033 lands at USD 20.88 billion and 2.75% — a full point off the base rate, not a market that stops growing.

The observation that would falsify this

If US reagent revenue for chemistry does not decline at the vendors through 2027 and 2028, then transmission is effectively zero, and the fee schedule is a transfer between laboratory and payer rather than a price event inside diagnostics. If it declines by more than the schedule implies, the laboratories are passing the whole cut upstream. The most recent disclosures point to the second — see our companion analysis of what Sysmex, Dirui and Mindray each did with a falling price per test.

Companion analyses in this cluster

• Sysmex Took 1.7 Per Cent Off Sales and 40.8 Per Cent Off Operating Profit — what a fee-schedule reset does to an installed base that was bought at yesterday’s price.
• KDIGO Turned a Dipstick Into a Chemistry Assay — the one place in this discipline where volume and price can rise together.
• Global Clinical Chemistry and Urinalysis Market Report, Size, Share and Forecast 2026-2033 — the full report: USD 16.8bn to USD 22.49bn at 3.71%, built bottom-up from six disclosed corporate pools with 51.1% stated as a residual.

About the method

70/30, secondary to primary. Every figure in this piece is carried by the secondary layer: the CMS preliminary payment file and accompanying fact sheet, the statutory phase-in as amended by the Consolidated Appropriations Act, 2026, the ACLA reading of the same file, and provincial procurement award notices from China. Our own primary programme for the underlying report — 41 depth interviews across 11 markets, 26 open-ended tender interviews, a 164-respondent laboratory survey and four conferences — is used for mechanism only: how a fee-schedule reduction is renegotiated inside a cost-per-reportable-result contract, how a provincial alliance sequences its specification list, and how long a laboratory waits before it changes an analyser over a reagent price. It never carries a figure. Where the primary and secondary layers disagree, the secondary layer wins and the disagreement is disclosed rather than smoothed. These programme parameters are stated so that they can be reconciled against programme records.

Sources

• Centers for Medicare & Medicaid Services, Preliminary Calendar Year 2027 Medicare Clinical Laboratory Fee Schedule Payment Rates, 21 September 2026.
• American Clinical Laboratory Association, Preliminary Medicare Laboratory Rates Based on Incomplete Data Underscore Urgent Need for the RESULTS Act, 21 September 2026.
• HFMA, 2027 Medicare lab fee schedule points to 15% cuts across many test codes, 22 September 2026.
• Trade reporting of the Jiangxi Provincial Medical Insurance Bureau award notice for sugar-metabolism and other biochemical testing reagents, Biochemical reagent centralized procurement landing, September 2026 — used for the award specification count and average reduction only; the vendor-company detail in that report is not relied on for any figure here.
• Roche Holding AG Annual Report 2025; Abbott Laboratories fourth-quarter and full-year 2025 results; QuidelOrtho Corporation fourth-quarter 2025 results; Siemens Healthineers fiscal 2025 results — used for the vendor-side growth rates referred to above.

Pheonix Research publishes no third-party market-research estimates. Where a published figure could not be traced to a primary document, it appears in this cluster as a stated residual rather than as an estimate borrowed from an unnamed source.